4 not yet recruiting, 3 recruiting, 1 unknown. 5 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Not yet recruiting 3, Recruiting 1, Unknown 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Antibody-drug Conjugates: new trials by email Literature Review of Antibody-drug Conjugates trials Research Report on Antibody-drug Conjugates
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer Disitamab Vedotin and Toripalimab, Toripalimab and Nab-Paclitaxel - Bladder (Urothelial, Transitional Cell) Cancer, Antibody-drug Conjugates | Phase 2 | Not yet recruiting | Tianjin Medical University Second Hospital | 150 | 2026-10-20 | 2026-10-16 |
| Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression Ovarian Cancer, Antibody-drug Conjugates | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 22 | 2026-09-01 | 2025-09-11 | |
| ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma Becotatug Vedotin, SBRT, Becotatug Vedotin or Sacituzumab Tirumotecan - Adenoid Cystic Carcinoma of the Head and Neck, SBRT | Phase 2 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 40 | 2026-05-01 | 2026-05-12 |
| MA-CRC-II-016 SHR-1811 SHR-A1811 & Bevacizumab injection, Chemotherapeutic Combinations - mCRC, HER2 | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 80 | 2025-12-30 | 2026-01-21 |
| Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies SHR-A1811, Trastuzumab Rezetecan - Urachal Cancer, Advanced Solid Tumor Cancer | Phase 2 | Recruiting | Sheng Zhang | 90 | 2025-12-18 | 2025-12-30 |
| Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients Medical-grade compression stocking - Urothelial Carcinoma, Advanced Solid Tumors | Not applicable | Recruiting | Sheng Zhang | 58 | 2025-08-30 | 2025-09-15 |
| RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC Disitamab Vedotin and Toripalimab - Muscle Invasive Bladder Cancer, HER2 Expression | Phase 2 | Unknown | RenJi Hospital | 6 | 2023-08-01 | 2023-08-31 |
| Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer Non-intervention research - Antibody-drug Conjugates, HER2-low Breast Cancer | Recruiting | Sun Yat-sen University | 700 | 2020-01-01 | 2025-03-20 |
Breast Neoplasms (1) · Carcinoma, Transitional Cell (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Paget Disease, Extramammary (1) · Urachal cancer (1)
Neoplasms (4) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Adnexal Diseases (1) · Breast Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1)
disitamab vedotin (2) · toripalimab (2) · 130-nm albumin-bound paclitaxel (1) · Bevacizumab (1) · Drug Therapy (1) · RC48 antibody (1)
Sheng Zhang (2) · Peking Union Medical College Hospital (1) · RenJi Hospital (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Sun Yat-sen University (1) · Tianjin Medical University Second Hospital (1)
China (5)
Haige Chen (1) · Jing Li, Doctor (1)